1. Javadian, P. et al. (2020) Endometrial carcinoma and its precursors. Adv. Exp. Med. Biol., 1242, 59–72.
2. Howlader, N. et al. SEER Cancer Statistics Review, 1975–2017, National Cancer Institute, Bethesda, MD. https://seer.cancer.gov/ csr/1975_2017/, based on November 2019 SEER data submission, posted to the SEER web site, April 2020.
3. Moore, K.N. et al. (2011) Uterine papillary serous carcinoma. Clin. Obstet. Gynecol., 54, 278–291.
4. Holman, L.L. et al. (2017) Factors prognostic of survival in advanced- stage uterine serous carcinoma. Gynecol. Oncol., 146, 27–33.
5. Kandoth, C. et al. (2013) Integrated genomic characterization of endometrial carcinoma. Nature, 497, 67–73.
6. Zhao, S. et al. (2013) Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc. Natl. Acad. Sci. USA, 110, 2916–2921.
7. Zhang, L. et al. (2020) Pathogenesis and clinical management of uterine serous carcinoma. Cancers (Basel), 12.
8. Kang, H.S. et al. (2011) GPR54 is a target for suppression of me- tastasis in endometrial cancer. Mol. Cancer Ther., 10, 580–590.
9. Kharma, B. et al. (2013) Utilization of genomic signatures to iden- tify high-efficacy candidate drugs for chemorefractory endometrial cancers. Int. J. Cancer., 133, 2234–2244.
10. Kharma, B. et al. (2014) STAT1 drives tumor progression in serous papillary endometrial cancer. Cancer Res., 74, 6519–6530.
11. Zeng, X. et al. (2019) Phosphorylation of STAT1 serine 727 enhances platinum resistance in uterine serous carcinoma. Int. J. Cancer., 145, 1635–1647.
12. Binnewies, M. et al. (2018) Understanding the tumor immune micro- environment (TIME) for effective therapy. Nat. Med., 24, 541–550.
13. Antomarchi, J. et al. (2019) Immunosuppressive tumor microenvi- ronment status and histological grading of endometrial carcinoma. Cancer Microenviron., 12, 169–179.
14. Hamanishi, J. et al. (2007) Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl. Acad. Sci. USA, 104, 3360–3365.
15. Hamanishi, J. et al. (2011) The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple im- mune factors. Clin. Immunol., 141, 338–347.
16. Li, K. et al. (2009) Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol. Immunother., 58, 641–652.
17. Hamanishi, J. et al. (2015) Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J. Clin. Oncol., 33, 4015–4022.
18. Peng, J. et al. (2015) Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-κB to foster an immunosuppressive tumor microenvironment in ovarian cancer. Cancer Res., 75, 5034–5045.
19. Pakish, J.B. et al. (2017) Immune microenvironment in microsatellite-instable endometrial cancers: hereditary or sporadic origin matters. Clin. Cancer Res., 23, 4473–4481.
20. Cai, Y. et al. (2019) Multi-omics profiling reveals distinct micro- environment characterization of endometrial cancer. Biomed. Pharmacother., 118, 109244.
21. Musacchio, L. et al. (2020C)aIrmcimnuongeencheesciks,p2o0in2t2i,nVhoibl.itXorXs:, aNpor.oXmX- ising choice for endometrial cancer patients? J. Clin. Med., 9.
22. Mulati, K. et al. (2019) VISTA expressed in tumour cells regulates T cell function. Br. J. Cancer., 120, 115–127.
23. Taki, M. et al. (2018) Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation. Nat. Commun., 9, 1685.
24. Blaisdell, A. et al. (2015) Neutrophils oppose uterine epithelial carcinogenesis via debridement of hypoxic tumor cells. Cancer Cell, 28, 785–799.
25. Yamanoi, K. et al. (2016) Suppression of ABHD2, identified through a functional genomics screen, causes anoikis resistance, chemoresistance and poor prognosis in ovarian cancer. Oncotarget, 7, 47620–47636.
26. Solito, S. et al. (2019) Methods to measure MDSC immune sup- pressive activity in vitro and in vivo. Curr. Protoc. Immunol., 124, e61.
27. Horikawa, N. et al. (2020) Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment. Br. J. Cancer, 122, 778–788.
28. Felix, K. (2016). Trim Galore. http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/ (20 March 2022, date last accessed).
29. Dobin, A. et al. (2013) STAR: ultrafast universal RNA-seq aligner. Bioinformatics, 29, 15–21.
30. Li, B. et al. (2011) RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinf., 12, 323.
31. Daikoku, T. et al. (2008) Conditional loss of uterine Pten unfail- ingly and rapidly induces endometrial cancer in mice. Cancer Res., 68, 5619–5627.
32. Li, B.L. et al. (2020) Prognostic significance of immune landscape in tumour microenvironment of endometrial cancer. J. Cell. Mol. Med., 24, 7767–7777.
33. Cheng, P. et al. (2021) Bioinformatic profiling identifies prognosis- related genes in the immune microenvironment of endometrial car- cinoma. Sci. Rep., 15.
34. Kortlever, R.M. et al. (2017) Myc cooperates with Ras by programming inflammation and immune suppression. Cell, 171, 1301– 1315.e14.
35. Casey, S.C. et al. (2016) MYC regulates the antitumor immune re- sponse through CD47 and PD-L1. Science, 352, 227–231.
36. Whitfield, J.R. et al. (2017) Strategies to inhibit Myc and their clinical applicability. Front. Cell Dev. Biol., 5, 10.
37. Truica, M.I. et al. (2021) Turning up the heat on MYC: progress in small-molecule inhibitors. Cancer Res., 81, 248–253.
38. Cheng, H. et al. (2014) A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition. Cancer Res., 74, 15–23.
39. Fedorko, A.M. et al. (2020) An immune competent orthotopic model of endometrial cancer with metastasis. Heliyon, 6, e04075.
40. Tseng, S.H. et al. (2020) Novel, genetically induced mouse model that recapitulates the histological morphology and immuno- suppressive tumor microenvironment of metastatic peritoneal carcinomatosis. J. ImmunoTher. Cancer., 8, e000480.
41. Liu, Y. et al. (2018) Crucial biological functions of CCL7 in cancer. PeerJ, 6, e4928.
42. Hao, Q. et al. (2020) CCL2/CCR2 signaling in cancer pathogen- esis. Cell Commun. Signal., 18, 82.
43. Yang, H. et al. (2020) CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis. Mol. Cancer, 19, 41.
44. Lahmar, Q. et al. (2021) Monocytic myeloid-derived suppressor cells home to tumor-draining lymph nodes via CCR2 and locally modulate the immune response. Cell. Immunol., 362, 104296.
45. Yuanyuan, L. et al. (2021) Myeloid NEMO deficiency promotes tumor immunosuppression partly via MCP1-CCR2 axis. Exp. Cell Res., 399, 112467.
46. Teng, K.Y. et al. (2017) Blocking the CCL2-CCR2 axis using CCL2- neutralizing antibody is an effective therapy for hepatocellular cancer in a mouse model. Mol. Cancer Ther., 16, 312–322.